International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(11), P. 9677 - 9677
Published: June 2, 2023
The
prevalence
of
metabolic-related
disorders,
such
as
non-alcoholic
fatty
liver
disease
(NAFLD)
and
type
2
diabetes
mellitus
(DM2),
has
been
increasing.
Therefore,
developing
improved
methods
for
the
prevention,
treatment,
detection
these
two
conditions
is
also
necessary.
In
this
study,
our
primary
focus
was
on
examining
role
chronic
inflammation
a
potential
link
in
pathogenesis
diseases
their
interconnections.
A
comprehensive
search
PubMed
database
using
keywords
"non-alcoholic
disease",
"type
mellitus",
"chronic
inflammation",
"pathogenesis",
"progression"
yielded
177
relevant
papers
analysis.
findings
study
revealed
intricate
relationships
between
NAFLD
DM2,
emphasizing
crucial
inflammatory
processes.
These
connections
involve
various
molecular
functions,
including
altered
signaling
pathways,
patterns
gene
methylation,
expression
related
peptides,
up-
downregulation
several
genes.
Our
foundational
platform
future
research
into
relationship
allowing
better
understanding
underlying
mechanisms
introducing
new
treatment
standards.
Biomedicines,
Journal Year:
2022,
Volume and Issue:
10(9), P. 2251 - 2251
Published: Sept. 11, 2022
The
triglyceride
and
glucose
index
(TyG
index),
a
marker
of
insulin
resistance,
is
positively
associated
with
NAFLD.
Modified
TyG
indices,
combining
body
composition
markers
including
body-mass
(BMI)
or
waist
circumference
(WC)
the
index,
are
reported
to
enhance
predictability
resistance.
This
study
aimed
compare
usefulness
modified
indices
for
predicting
NAFLD
fatty
liver
(FLI).
cross-sectional
included
12,757
Korean
adults.
FLI
were
calculated
using
established
formulas,
TyG-BMI
TyG-WC
as
×
BMI
WC,
respectively.
All
measures
divided
into
quartiles.
severity
(grade
0-3)
was
compared
ANOVA
by
quartiles
each
index.
Odds
ratios
(ORs)
95%
confidence
intervals
(CIs)
multiple
logistic
regression
analysis.
ROC
AUROC
analyses
performed
BMI,
TyG,
TyG-BMI,
TyG-WC,
FLI.
A
higher
grade
ORs
increased
in
all
especially
(39.251
(31.304-49.215))
(38.937
(31.145-48.678)).
0.848
(0.840-0.855)
0.850
(0.842-0.857)
reliable
indicator
presence
World Journal of Gastroenterology,
Journal Year:
2022,
Volume and Issue:
28(26), P. 3243 - 3257
Published: July 7, 2022
Sodium
glucose
cotransporter-2
inhibitors
(SGLT2-I)
are
the
most
recently
approved
drugs
for
type
2
diabetes
(T2D).
Recent
clinical
trials
of
these
compounds
reported
beneficial
cardiovascular
(CV)
and
renal
outcomes.
A
major
cause
vascular
dysfunction
CV
disease
in
is
hyperglycemia
associated
with
inflammation
oxidative
stress.
Pre-clinical
studies
demonstrated
that
SGLT2-I
reduce
glucotoxicity
promote
anti-inflammatory
effects
by
lowering
stress.To
investigate
on
markers
stress,
inflammation,
liver
steatosis,
fibrosis
patients
T2D
non-alcoholic
fatty
(NAFLD).We
referred
fifty-two
consecutive
outpatients
treated
metformin
monotherapy
exhibiting
poor
glycemic
control
to
our
centre.
We
introduced
an
(dapagliflozin,
empagliflozin,
or
canagliflozin;
n
=
26)
a
different
hypoglycemic
drug
[other
glucose-lowering
(OTHER),
26].
evaluated
circulating
interleukins
serum
hydroxynonenal
(HNE)-
malondialdehyde
(MDA)-protein
adducts,
index
(FLI),
NAFLD
score,
aspartate
aminotransferase
(AST)/alanine
(ALT)
ratio,
AST-to-platelet-ratio
(APRI),
fibrosis-4
day
before
(T0)
following
treatment
six
months
(T1).
also
performed
transient
elastography
at
T0
T1.Add-on
therapy
resulted
improved
reduced
fasting
blood
both
groups.
Of
note,
months,
reduction
FLI
APRI,
as
well
FibroScan
result,
was
SGLT2-I,
but
not
OTHER
group;
furthermore,
group,
we
lower
levels
interleukin
(IL)-1β,
IL-6,
tumor
necrosis
factor,
endothelial
growth
monocyte
chemoattractant
protein-1,
higher
IL-4
IL-10.
did
observe
any
modification
group.
Finally,
HNE-
MDA-protein
adducts
decreased
significantly
rather
than
correlated
steatosis
scores.The
present
data
indicate
improvement
pro-inflammatory
redox
status,
more
optimizing
control.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(5), P. 1852 - 1852
Published: Feb. 26, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
serious
health
problem
due
to
its
high
incidence
and
consequences.
In
view
of
the
existing
controversies,
new
therapeutic
options
for
NAFLD
are
still
being
sought.
Therefore,
aim
our
review
was
evaluate
recently
published
studies
on
treatment
patients.
We
searched
articles
in
PubMed
database
using
appropriate
terms,
including
“non-alcoholic
disease”,
“nonalcoholic
“NAFLD”,
“diet”,
“treatment”,
“physical
activity”,
“supplementation”,
“surgery”,
“overture”
“guidelines”.
One
hundred
forty-eight
randomized
clinical
trials
from
January
2020
November
2022
were
used
final
analysis.
The
results
show
significant
benefits
therapy
associated
with
use
not
only
Mediterranean
but
also
other
types
diet
(including
low-calorie
ketogenic,
high-protein,
anti-inflammatory
whole-grain
diets),
as
well
enrichment
selected
food
products
or
supplements.
Significant
this
group
patients
moderate
aerobic
physical
training.
available
indicate,
above
all,
usefulness
drugs
related
weight
reduction,
reduction
insulin
resistance
lipids
level
antioxidant
properties.
dulaglutide
combination
tofogliflozin
pioglitazone
should
be
emphasized.
Based
latest
research,
authors
article
suggest
revision
recommendations
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(11), P. 9677 - 9677
Published: June 2, 2023
The
prevalence
of
metabolic-related
disorders,
such
as
non-alcoholic
fatty
liver
disease
(NAFLD)
and
type
2
diabetes
mellitus
(DM2),
has
been
increasing.
Therefore,
developing
improved
methods
for
the
prevention,
treatment,
detection
these
two
conditions
is
also
necessary.
In
this
study,
our
primary
focus
was
on
examining
role
chronic
inflammation
a
potential
link
in
pathogenesis
diseases
their
interconnections.
A
comprehensive
search
PubMed
database
using
keywords
"non-alcoholic
disease",
"type
mellitus",
"chronic
inflammation",
"pathogenesis",
"progression"
yielded
177
relevant
papers
analysis.
findings
study
revealed
intricate
relationships
between
NAFLD
DM2,
emphasizing
crucial
inflammatory
processes.
These
connections
involve
various
molecular
functions,
including
altered
signaling
pathways,
patterns
gene
methylation,
expression
related
peptides,
up-
downregulation
several
genes.
Our
foundational
platform
future
research
into
relationship
allowing
better
understanding
underlying
mechanisms
introducing
new
treatment
standards.
